PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Medical Hypotheses

• Publication date

  2013-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.mehy.2013.09.022PMID 24120699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal graft outcome in autosomal dominant medullary cystic kidney disease type 1.

  2013cited by this paper
• MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis

  2013cited by this paper
• Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma

  2013cited by this paper
• NF-κB Repression by PIAS3 Mediated RelA SUMOylation

  2012cited by this paper
• Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection

  2012cited by this paper
• [Expression of STAT3 and PIAS3 in renal tissues of MRL/lpr mice].

  2012cited by this paper
• PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• TRIM8 modulates STAT3 activity through negative regulation of PIAS3

  2010cited by this paper
• Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study.

  2010cited by this paper
• N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.

  2010cited by this paper
• PIAS proteins: pleiotropic interactors associated with SUMO

  2009cited by this paper
• A Specific Epitope of Protein Inhibitor of Activated STAT3 Is Responsible for the Induction of Apoptosis in Rat Transformed Mast Cells1

  2009cited by this paper
• Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription‐3 with epidermal growth factor receptor blockade in lung cancer

  2009cited by this paper
• Aberrant Methylation of APC, MGMT, RASSF2A, and Wif-1 Genes in Plasma as a Biomarker for Early Detection of Colorectal Cancer

  2009cited by this paper
• PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.

  2009cited by this paper
• Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies.

  2009cited by this paper
• Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression

  2008cited by this paper
• Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

  2007cited by this paper
• Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.

  2006cited by this paper
• Differential PIAS3 expression in human malignancy.

  2004cited by this paper
• Cancer of the gastrointestinal tract: early detection or early prevention?

  2004cited by this paper
• NMR Structure of the N-terminal Domain of SUMO Ligase PIAS1 and Its Interaction with Tumor Suppressor p53 and A/T-rich DNA Oligomers*

  2004cited by this paper
• Protein modification by SUMO.

  2004cited by this paper
• PIAS3 Suppresses NF-κB-mediated Transcription by Interacting with the p65/RelA Subunit*

  2004cited by this paper
• Regulation of JAK–STAT signalling in the immune system

  2003cited by this paper
• Increased K+ Efflux and Apoptosis Induced by the Potassium Channel Modulatory Protein KChAP/PIAS3β in Prostate Cancer Cells*

  2002cited by this paper
• PIAS3 (protein inhibitor of activated STAT‐3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2

  2002cited by this paper
• Role for Microphthalmia Transcription Factor in the Diagnosis of Metastatic Malignant Melanoma

  2002cited by this paper
• A New Role for the STAT3 Inhibitor, PIAS3

  2002cited by this paper
• Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1

  2002cited by this paper
• Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells

  2001cited by this paper
• A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases.

  2001cited by this paper
• Isolation and chromosomal assignment of a human gene encoding protein inhibitor of activated STAT3 (PIAS3)

  1999cited by this paper
• Specific inhibition of Stat3 signal transduction by PIAS3.

  1997cited by this paper
• Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

  1993cited by this paper
• Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.

  1993cited by this paper
• Characterization of SAF‐A, a novel nuclear DNA binding protein from HeLa cells with high affinity for nuclear matrix/scaffold attachment DNA elements.

  1992cited by this paper

• Multi-omics analysis reveals PIAS family gene dysregulation as a driver of head and neck squamous cell carcinoma (HNSC) progression and therapeutic vulnerability

  2025cites this paper
• Sumoylation of cyclin and its therapeutic potential for cancer

  2025cites this paper
• PIAS family in cancer: from basic mechanisms to clinical applications

  2024cites this paper
• SUMOylation at the crossroads of gut health: insights into physiology and pathology

  2024cites this paper
• Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

  2023cites this paper
• Negative regulators of STAT3 signaling pathway in cancers

  2019influential citation
• The role of protein inhibitor of activated STAT3 and miRNA-18a expressions in breast cancer

  2019cites this paper
• Negative regulators of STAT3 signaling pathway in cancers

  2019influential citation
• PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation

  2018cites this paper
• The Role of the JAK/STAT Signalling Pathway in Immunoregulation of Gastrointestinal Cancers

  2017cites this paper
• The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer

  2016cites this paper
• Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression.

  2016cites this paper
• Protein Inhibitor of Activated STAT3 Regulates Migration, Invasion, and Activation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis

  2016cites this paper
• Rheumatoid Arthritis Activation of Fibroblast-like Synoviocytes in Regulates Migration, Invasion, and Protein Inhibitor of Activated STAT3

  2015cites this paper
• Methionine adenosyltransferase α2 sumoylation positively regulate Bcl-2 expression in human colon and liver cancer cells

  2015cites this paper
• SUMO pathway components as possible cancer biomarkers.

  2015cites this paper
• Association of sedentary behavior with the expression levels of biomarkers in colorectal cancer: clinical analysis of 228 patients.

  2014cites this paper
• Biology of Human Tumors Low PIAS 3 Expression in Malignant Mesothelioma Is Associated with Increased STAT 3 Activation and Poor Patient Survival

  2014cites this paper
• Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival

  2014cites this paper